TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - TELA Bio, Inc. has announced a registered direct offering of common stock and pre-funded warrants, aiming to raise approximately $13.0 million for various corporate purposes [1][2]. Group 1: Offering Details - The offering consists of 4,189,000 shares of common stock priced at $1.11 per share and pre-funded warrants for 7,523,000 shares at $1.1099 each [1]. - The gross proceeds from the offering are expected to be around $13.0 million, assuming no exercise of the pre-funded warrants [1]. - The offering is anticipated to close on or about November 17, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - TELA intends to utilize the net proceeds for general corporate purposes, including sales and marketing, research and development, general and administrative expenses, working capital, and capital expenditures [2]. Group 3: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of the patient's anatomy [5]. - The company aims to provide advanced and economically effective solutions that leverage the patient's natural healing response while minimizing long-term exposure to synthetic materials [5].